Fortress Biotech Inc (FBIO) Stock Rating Upgraded by Zacks Investment Research


The brokerage presently has a $4.50 price target on the biopharmaceutical company's stock. Zacks Investment Research 's price target suggests a potential upside of 18.11% from the stock's previous close.



from Biotech News